PERSPECTIVE THERAPEUTICS, INC. Proceeds from Common Stock Issued
PERSPECTIVE THERAPEUTICS, INC. (CATX) had Proceeds from Common Stock Issued of $10.20 million as of 2025-02-18, per its 10-K filed 2026-03-16.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-03-16
- PERSPECTIVE THERAPEUTICS, INC. proceeds from issuance of common stock for the quarter ending 2022-06-30 was $0.00.
- PERSPECTIVE THERAPEUTICS, INC. proceeds from issuance of common stock for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- PERSPECTIVE THERAPEUTICS, INC. proceeds from issuance of common stock for the quarter ending 2021-03-31 was $47.90M.
- PERSPECTIVE THERAPEUTICS, INC. proceeds from issuance of common stock for the quarter ending 2019-03-31 was -$11.00K.
- PERSPECTIVE THERAPEUTICS, INC. proceeds from issuance of common stock for fiscal 2024 was $275.81M, a 75671.15% increase from fiscal 2023.
- PERSPECTIVE THERAPEUTICS, INC. proceeds from issuance of common stock for fiscal 2023 was $364.00K.
- PERSPECTIVE THERAPEUTICS, INC. proceeds from issuance of common stock for fiscal 2022 was $0.00.
- PERSPECTIVE THERAPEUTICS, INC. proceeds from issuance of common stock for fiscal 2022 was $0.00.
| Period end | Proceeds from Issuance of Common Stock | Proceeds from Issuance of Common Stock as first filed | Proceeds from Issuance of Common Stock 0 month | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|---|---|---|
| 2025-02-18 | $10.20M 10-K · filed 2026-03-16 | ||||||
| 2024-12-31 | $275.81M 10-K/A · filed 2025-03-28 | ||||||
| 2023-12-31 | $364.00K 10-K/A · filed 2025-03-28 | ||||||
| 2022-12-31 | $0.00 10-K · filed 2024-03-28 | $0.00 10-K · filed 2024-03-28 | |||||
| 2022-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $0.00 derived: sum of 2 quarters · filed 2024-03-28 | $0.00 10-K · filed 2024-03-28 | ||||
| 2022-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-13 | $0.00 10-Q · filed 2022-05-13 | |||||
| 2021-12-31 | $0.00 10-Q · filed 2022-02-09 | ||||||
| 2021-03-31 | $47.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-13 | $56.38M 10-Q · filed 2022-05-13 | |||||
| 2021-02-08 | $51.75M 10-KT · filed 2023-05-01 | $45.00M 10-Q · filed 2021-05-14 | |||||
| 2020-12-31 | $8.47M 10-Q · filed 2022-02-09 | ||||||
| 2020-10-22 | $9.50M 10-KT · filed 2023-05-01 | ||||||
| 2019-03-31 | -$11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-13 | -$124.00K derived: sum of 2 quarters · filed 2020-05-13 | $7.37M 10-Q · filed 2020-05-13 | ||||
| 2018-12-31 | -$113.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-12 | $7.38M 10-Q · filed 2020-02-12 | |||||
| 2018-09-30 | $7.49M 10-Q · filed 2019-11-13 | ||||||
| 2018-07-11 | $8.25M 10-Q · filed 2018-11-09 | ||||||
| 2018-06-30 | $479.00K 10-K · filed 2018-09-26 | ||||||
| 2016-06-30 | $0.00 10-K · filed 2016-09-09 | ||||||
| 2015-06-30 | $0.00 10-K · filed 2016-09-09 | ||||||
| 2014-06-30 | -$4.18K derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-09 | $13.81M 10-K · filed 2016-09-09 | |||||
| 2014-03-31 | $13.82M 10-Q · filed 2015-05-15 | ||||||
| 2013-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-09-14 | $0.00 derived: sum of 2 quarters · filed 2015-09-14 | $0.00 derived: sum of 3 quarters · filed 2015-09-14 | $3.29M 10-K · filed 2015-09-14 | |||
| 2013-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-15 | $0.00 derived: sum of 2 quarters · filed 2014-05-15 | $3.29M 10-Q · filed 2014-05-15 | $3.29M derived: sum of 4 quarters · filed 2014-05-15 | |||
| 2012-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-02-14 | $3.29M 10-Q · filed 2014-02-14 | $3.29M derived: sum of 3 quarters · filed 2014-02-14 | $3.29M derived: sum of 4 quarters · filed 2014-02-14 | |||
| 2012-09-30 | $3.29M 10-Q · filed 2013-11-14 | $3.29M derived: sum of 2 quarters · filed 2013-11-14 | $3.29M derived: sum of 3 quarters · filed 2013-11-14 | ||||
| 2012-07-13 | $3.29M 10-K · filed 2013-09-30 | ||||||
| 2012-06-30 | $1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-09-30 | -$5.21K derived: sum of 2 quarters · filed 2013-09-30 | $2.27M 10-K · filed 2013-09-30 | ||||
| 2012-03-31 | -$5.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-05-15 | $2.27M 10-Q · filed 2013-05-15 | |||||
| 2011-12-31 | $2.28M 10-Q · filed 2013-02-14 | ||||||
| 2011-12-07 | $261.12K 10-K · filed 2013-09-30 | ||||||
| 2011-10-19 | $2.01M 10-K · filed 2013-09-30 | ||||||
| 2011-06-30 | -$118.15K derived: 10-K/A 12 month − 10-Q 9 month · filed 2012-10-26 | -$118.15K derived: sum of 2 quarters · filed 2012-10-26 | $250.63K 10-K/A · filed 2012-10-26 | ||||
| 2011-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-05-15 | $368.78K 10-Q · filed 2012-05-15 | |||||
| 2010-12-31 | $368.78K 10-Q · filed 2012-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |